{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T10:07:40Z","timestamp":1657015660971},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.ncl.2006.01.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:06:46Z","timestamp":1168441606000},"page":"199-214","source":"Crossref","is-referenced-by-count":2,"title":["Diagnosis and Management of Multiple Sclerosis: Case Studies"],"prefix":"10.1016","volume":"24","author":[{"given":"Douglas A.","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Olek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot M.","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2006.01.002_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Aclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2006.01.002_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","article-title":"High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis","volume":"121","author":"Beck","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ncl.2006.01.002_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/135245850100700603","article-title":"Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS","volume":"7","author":"Tintore","year":"2001","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1191\/1352458503ms847oa","article-title":"Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings","volume":"9","author":"Sastre-Garriga","year":"2003","journal-title":"Mult Scler"},{"issue":"Pt 11","key":"10.1016\/j.ncl.2006.01.002_bib5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","article-title":"Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis","volume":"120","author":"Barkhof","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2006.01.002_bib6","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000082654.99838.EF","article-title":"The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Frohman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2006.01.002_bib8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2006.01.002_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10072-003-0190-3","article-title":"Long-term interferon-beta treatment for multiple sclerosis","volume":"24","author":"Ruggieri","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2006.01.002_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/135245859900500309","article-title":"Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis","volume":"5","author":"Mohr","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1191\/1352458504ms1002oa","article-title":"Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management","volume":"10","author":"Frohman","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00127893-200207000-00003","article-title":"Disease-modifying therapy in multiple sclerosis: strategies for optimizing management","volume":"8","author":"Frohmann","year":"2002","journal-title":"Neurologist"},{"key":"10.1016\/j.ncl.2006.01.002_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/01.WNL.0000166049.51502.6A","article-title":"Appearance and disappearance of neutralizing antibodies during interferon-beta therapy","volume":"65","author":"Sorensen","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/01.wnl.0000171748.48188.5b","article-title":"Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS","volume":"65","author":"Francis","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/01.wnl.0000171747.59767.5c","article-title":"Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study","volume":"65","author":"Kappos","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.57.7.1239","article-title":"Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS","volume":"57","author":"Zivadinov","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","article-title":"The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis","volume":"63","author":"Morrow","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/WNL.53.9.2093","article-title":"Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis","volume":"53","author":"Metz","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2006.01.002_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-510X(99)00304-4","article-title":"The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis","volume":"173","author":"Sharrack","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2006.01.002_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-1331.2005.00988.x","article-title":"Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis","volume":"12","author":"Zorzon","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2006.01.002_bib22","first-page":"1255","article-title":"The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients","volume":"252","author":"Reggio","year":"2005","journal-title":"Twenty-four months follow-up. J Neurol"},{"key":"10.1016\/j.ncl.2006.01.002_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2004.04.026","article-title":"Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS","volume":"223","author":"Smith","year":"2004","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2006.01.002_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000113395","article-title":"Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study","volume":"38","author":"Cavazzuti","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2006.01.002_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000074912","article-title":"Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment","volume":"51","author":"Lus","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2006.01.002_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.58.2.314","article-title":"An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS","volume":"58","author":"Calabresi","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","article-title":"The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Goodin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","article-title":"Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study","volume":"54","author":"Likosky","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2006.01.002_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","author":"The Canadian Cooperative Multiple Sclerosis Study Group","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2006.01.002_bib31","first-page":"403","article-title":"Treatment of progressive multiple sclerosis with pulse cyclophosphamide\/methylprednisolone: response to therapy is linked to the duration of progressive disease","volume":"5","author":"Hohol","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1212\/WNL.43.5.910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2006.01.002_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1191\/1352458505ms1172sr","article-title":"One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis","volume":"11","author":"Zephir","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2006.01.002_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386190600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386190600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T17:13:37Z","timestamp":1556039617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386190600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S073386190600003X"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2006.01.002","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}